Loading…
Autonomix Medical, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in AMIX.
▼ -99.8% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 3 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2026 | 2025 | 2024 |
|---|---|---|---|---|
| Year-end price | $4.02 | $11.55 | $78.96 | |
| P/B | 0.4x | 0.4x | 0.2x | 0.5x |
| EPS | -$48.72 | -$135.66 | -$311.22 | |
| ROE | -202.23% | -283.55% | -140.88% | -202.23% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| PCSAProcessa Pharmaceuticals, Inc. | $1.84 | 2.8x | — | — | -464.20% | $5.14M |
| POASPHAOS TECHNOLOGY HOLDINGS (CAYMAN) Ltd | $0.17 | — | — | — | — | $5.21M |
| BRTXBioRestorative Therapies, Inc. | $0.20 | — | 1.7x | — | -241.14% | $5.07M |
| ERNAErnexa Therapeutics Inc. |
Autonomix Medical, Inc., a development stage medical device company, focuses on advancing technologies for sensing and treating disorders of nervous system. The company's technology platform includes a catheter-based system incorporating microchip-enabled sensing architecture designed to detect low-amplitude neural signals from within the vascular system. It develops technology for patients with pancreatic cancer and addresses indications for chronic pain management, hypertension, cardiovascular, and other nerve-related disorders. Autonomix Medical, Inc. was incorporated in 2014 and is headquartered in The Woodlands, Texas.
Company description provided by Yahoo Finance.
| $4.57 |
| — |
| 0.8x |
| — |
| -320.72% |
| $5.33M |
| MLECMoolec Science SA | $6.80 | — | 9.7x | — | — | $4.94M |
| LABTLakewood-Amedex Biotherapeutics Inc. | $2.30 | — | 1.2x | — | -402.83% | $5.45M |